8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2015

Shire plc

_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

_________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01. Other Events

Shire plc have issued the press releases attached hereto as Exhibit 99.1 and Exhibit 99.2 which are incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

(d)  Exhibits.  The following exhibits are filed herewith:

99.1 Press Release dated May 1, 2015

99.2 Press Release dated May 1, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ M Enyedy
	Name:	Mark Enyedy
	Title:	Company Secretary

Dated: May 4, 2015

EXHIBIT INDEX
Number	Description
99.1	Press Release dated May 1, 2015
99.2	Press Release dated May 1, 2015

EX-99.1

Exhibit 99.1

Press Release

www.shire.com

Director/PDMR Share Dealings

May 1, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that on April 30, 2015, Stock Appreciation Rights (“SARs”) and Restricted Stock Units (“RSUs”) were granted to Persons Discharging Managerial Responsibilities (“PDMRs”) under the Shire Long Term Incentive Plan 2015 (“LTIP”). SARs and RSUs will normally vest after three years, subject to any performance conditions being satisfied, with no consideration payable on these awards. The awards were granted over notional American Depositary Shares (“ADSs”) in the Company as follows:

PDMR	Type of Award(1),(2)	Number of ADSs(3)	Exercise Price
Flemming Ornskov	SAR	26,398	$245.48
	RSU	19,799	Nil
Jeff Poulton	SAR	8,862	$245.48
	RSU	6,646	Nil
Mark Enyedy	SAR	4,444	$245.48
	RSU	4,191	Nil
Ginger Gregory	SAR	4,259	$245.48
	RSU	4,016	Nil
Phil Vickers	SAR	4,259	$245.48
	RSU	4,016	Nil

(1)   SARs and RSUs granted under the LTIP correspond to SARs and Performance Share Awards (“PSAs”) granted under the legacy Shire Portfolio Share Plan, as referenced in the Directors’ Remuneration Report in the 2014 Annual Report and Accounts.

(2)   SARs and RSUs granted to Dr. Ornskov and Mr. Poulton and RSUs granted to the remainder of the PDMRs are subject to performance conditions. Upon normal vesting, any ADSs to be delivered to Dr. Ornskov and Mr. Poulton will be subject to a retention period of two years in accordance with the rules of the LTIP.

(3)   One ADS is equal to three Ordinary Shares of 5 pence each in the Company.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

For further information please contact:

Investor Relations
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

EX-99.2

Exhibit 99.2

Press Release

www.shire.com

Total Voting Rights

May 1, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following:

As at April 30, 2015, the Company’s issued ordinary share capital comprised 591,651,753 ordinary shares of 5 pence each with voting rights and a further 8,653,004 ordinary shares held in treasury.

Therefore the total number of voting rights in the Company is 591,651,753. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Sarah Elton-Farr	seltonfarr@shire.com	+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX